Our Pricing

Complete Wegovy Starter Dose Escalation Protocol for UK Patients

Published on: June 03, 2026

If you're searching for a comprehensive wegovy starter dose guide uk, you've found the right resource. At Cured Pharmacy, our UK-registered clinical team has guided thousands of patients through the Wegovy dose escalation protocol, ensuring safe initiation from £79.00 with transparent pricing and expert pharmaceutical support throughout your treatment journey.

Understanding the Wegovy Starter Dose Protocol

Wegovy (semaglutide 2.4mg) follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes [1]. The starter dose begins at 0.25mg weekly for four weeks, gradually increasing every four weeks until reaching the maintenance dose of 2.4mg. This gradual titration allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation.

Clinical data from the STEP trials demonstrated that this escalation schedule significantly reduces the incidence of nausea and vomiting compared to immediate high-dose initiation [1]. The protocol isn't arbitrary—it's evidence-based medicine designed to balance efficacy with tolerability. Each dose level serves a specific physiological purpose, allowing GLP-1 receptors in your gut and brain to adapt progressively.

UK prescribers follow MHRA-approved dosing guidelines strictly. Your Cured Pharmacy clinical assessment determines whether Wegovy is appropriate for your individual circumstances, and our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets regulatory standards before dispensing.

Wegovy Pen Colours and Dosing Schedule UK

Each Wegovy dose comes in a distinctly coloured pen to prevent dosing errors—a critical safety feature when managing four different strengths. The starter pack contains four single-use pens, each delivering one weekly injection. Understanding the colour-coding system helps you track your progression through the escalation protocol.

The complete Wegovy dosing schedule follows this pattern: 0.25mg (pale blue pen) for weeks 1-4, 0.5mg (pale green pen) for weeks 5-8, 1.0mg (pink pen) for weeks 9-12, 1.7mg (yellow pen) for weeks 13-16, and finally 2.4mg (dark blue pen) from week 17 onwards as your maintenance dose. Each transition occurs after completing a full four-week cycle at the previous dose level.

In the STEP-1 trial, participants following this exact escalation protocol achieved an average 14.9% body weight reduction over 68 weeks, with 83.5% of patients reaching at least 5% weight loss [1][2]. The gradual dose increases were essential to these outcomes—patients who adhered to the schedule experienced significantly better tolerability profiles.

What If You Miss a Dose During Escalation?

If you miss a scheduled Wegovy injection and fewer than five days have passed, administer the missed dose as soon as you remember, then resume your regular weekly schedule. If more than five days have elapsed, skip the missed dose entirely and inject your next dose on the originally scheduled day—never double up to compensate.

During the starter dose escalation phase, missing doses can affect your tolerance to the next dose level. If you've missed two consecutive weekly injections, contact your UK prescriber before proceeding to the next dose strength. Your clinical team may recommend restarting at a lower dose to maintain tolerability and minimise gastrointestinal symptoms.

How to Use Your Wegovy Starter Pen Correctly

Wegovy pens are pre-filled, single-use devices requiring no dose dialling—each pen delivers the exact dose automatically. Before your first injection, allow the pen to reach room temperature for approximately 30 minutes after removing it from refrigeration. This reduces injection site discomfort and ensures proper medication flow.

The injection technique is straightforward: cleanse your chosen injection site (abdomen, thigh, or upper arm) with an alcohol wipe, remove both pen caps, place the pen perpendicular to your skin, press firmly until you hear a click, then hold for six seconds whilst watching the yellow indicator bar. The bar must fully appear in the dose window to confirm complete delivery [3].

Rotate injection sites weekly to prevent lipohypertrophy—a thickening of subcutaneous tissue that can impair semaglutide absorption. Many patients establish a rotation pattern (left abdomen, right abdomen, left thigh, right thigh) to ensure they don't inject into the same site more than once monthly. Proper technique maximises medication efficacy and minimises local reactions.

Storage Requirements for Wegovy Pens

Unopened Wegovy pens must be stored in a refrigerator between 2°C and 8°C until first use. Never freeze the pens—frozen semaglutide loses therapeutic potency and must be discarded. Once you've removed a pen from the refrigerator for injection, it can remain at room temperature (up to 30°C) for up to 28 days, though most patients use each pen immediately.

Keep pens in their original carton to protect from light, and always check the expiry date before administration. If you're travelling, Wegovy can be kept in an insulated cool bag with ice packs, but ensure the medication doesn't come into direct contact with ice. Our pharmacy team can advise on travel-specific storage solutions during your consultation.

Managing Side Effects During Wegovy Starter Doses

Gastrointestinal side effects—particularly nausea, diarrhoea, and constipation—are most common during the initial dose escalation phases. In the STEP trials, 44% of participants reported nausea, though most cases were mild to moderate and resolved within the first few weeks at each new dose level [1]. The gradual escalation protocol specifically aims to minimise these effects.

Practical strategies significantly improve tolerability: eat smaller, more frequent meals rather than three large ones; avoid high-fat and spicy foods during the first week after each dose increase; stay well-hydrated throughout the day; and consider taking anti-nausea medication if symptoms persist beyond 72 hours post-injection. Many patients find that symptoms peak 24-48 hours after injection, then gradually subside.

If side effects become severe or intolerable at any dose level, contact your UK prescriber immediately. Your clinical team may recommend extending the current dose phase for an additional four weeks before escalating, or in rare cases, stepping back to the previous dose. The protocol allows flexibility—your safety and comfort take precedence over rigid adherence to timelines.

When to Progress to Wegovy Maintenance Dose

You'll progress to the 2.4mg maintenance dose after completing 16 weeks of dose escalation, provided you've tolerated each preceding dose level adequately. The maintenance phase represents the therapeutic dose demonstrated in clinical trials to produce optimal weight loss outcomes—this is where Wegovy's full efficacy manifests [2].

Some UK prescribers may recommend remaining at the 1.7mg dose if you've achieved satisfactory weight loss and experienced significant side effects at higher doses. Clinical guidance suggests that patients losing 5% or more of their body weight at lower doses, with good tolerability, may not require escalation to 2.4mg. This individualised approach prioritises your specific response over protocol rigidity.

Long-term data from the STEP-5 trial showed sustained weight loss over 104 weeks in patients maintaining the 2.4mg dose, with an average reduction of 15.2% from baseline body weight [4]. Continued treatment at maintenance dose appears essential—weight regain commonly occurs after discontinuation, highlighting the chronic nature of obesity management.

Monitoring Your Progress Through Escalation

Regular monitoring helps assess treatment response and tolerability. Weigh yourself weekly at the same time of day, preferably first thing in the morning, and track measurements in a journal or app. Your UK clinical team will typically schedule follow-up consultations at 12 weeks and 24 weeks to evaluate efficacy and determine whether continued treatment is appropriate.

NICE guidance suggests discontinuing Wegovy if you haven't achieved at least 5% weight loss after 12 weeks on the maintenance dose, as further treatment is unlikely to produce clinically meaningful outcomes. This evidence-based threshold ensures appropriate resource allocation and helps identify patients who may benefit from alternative interventions.

Wegovy Starter Dose Guide UK: Cost and Access at Cured Pharmacy

At Cured Pharmacy, Wegovy treatment starts from £79.00, representing competitive UK pricing with complete transparency—you'll see the exact cost before completing your clinical assessment. This includes your medication, UK prescriber consultation, and discreet delivery to your preferred address. There are no hidden fees or surprise charges at checkout.

Your online consultation takes under three minutes and is reviewed by UK-registered prescribers who assess your medical history, current medications, and weight loss goals. If Wegovy is deemed clinically appropriate, your prescription is sent electronically to our pharmacy team for dispensing. Tarun Kumar, our superintendent pharmacist (GPhC 2233073), personally oversees quality assurance for every prescription.

We supply only genuine UK-licensed Wegovy manufactured by Novo Nordisk, sourced through authorised UK pharmaceutical wholesalers. Every pen includes full patient information leaflets, disposal guidance, and access to our pharmacy team for ongoing support throughout your treatment journey. Our GPhC registration (9012511) guarantees regulatory compliance and patient safety at every step.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine in the UK and must be prescribed following appropriate clinical evaluation of your individual circumstances.